Reata Pharma (RETA) Tops Q1 EPS by 82c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq rise as tech stocks gain ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Reata Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs
May 10, 2022 6:40 AM EDTCompleted Rolling Submission of NDA for Omaveloxolone for Treatment of Patients with Friedreichs Ataxia; Actively Preparing for Commercial Launch
Updates Outcome of Type A Meeting with the FDA on the Protocol Amendment for FALCON
Reaffirms Cash Runway Through end of 2024
Conference Call with Management on May 10, 2022, at 8:30 a.m. ET
PLANO, Texas--(BUSINESS... More



